Previous close | 12.74 |
Open | 12.61 |
Bid | 12.62 x 100 |
Ask | 12.71 x 100 |
Day's range | 12.60 - 12.67 |
52-week range | 9.05 - 14.50 |
Volume | |
Avg. volume | 41,075 |
Market cap | 526.452M |
Beta (5Y monthly) | 0.18 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.28 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 28.66 |
Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis Ocul
ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the Bank of America Healthcare Conference taking place on May 14-16, 2024 in Las Vegas, NV. Riad Sherif, M.D., Chief Executive Officer of Oculis, will deliver a company presentation on Wednesday
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares to Icelandic institutional and existing investorsBecomes second company dual-listed on NASDAQ U.S. and NASDAQ Iceland Main Market, trading under the symbol “OCS” beginning April 23, 2024Oculis will ring the Nasdaq Iceland opening bell on April 23, 2024, at 9:30 GMTPhase 2b RELIEF trial of OCS-02 (Licaminlimab) in Dry Eye Disease (DED) remains on track to readout in Q2 2024 ZUG, Switzerland, Apr